Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 25 April 2018

Indication(s)

- Helicobacter Test INFAI 75 mg powder for oral solution
- Helicobacter Test INFAI 75 mg powder for oral solution
- Helicobacter Test INFAI 75 mg powder for oral solution:


Helicobacter Test INFAI may be used for in vivo diagnosis of gastroduodenal Helicobacter pylori infection in:
- adults,
- adolescents, who are likely to have peptic ulcer disease.

This medicinal product is for diagnostic use only.



- Helicobacter Test INFAI for children of the age 3-11 45 mg powder for oral solution:

Helicobacter Test INFAI for children of the age 3-11 may be used for in vivo diagnosis of gastroduodenal Helicobacter pylori infection:
- for the evalutation of the success of eradication treatment, or,
- when invasive tests cannot be performed, or
- when there are discordant results arising from invasive tests.

This medicinal product is for diagnostic use only.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Cystic Fibrosis Knowledge Centre

Cystic Fibrosis Knowledge Centre

View disease awareness information, treatment options and European Cystic Fibrosis Society best practice guidelines.

Inflammatory Bowel Disease Knowledge Centre

Inflammatory Bowel Disease Knowledge Centre

The Inflammatory Bowel Disease (IBD) Knowledge Centre contains key information relating to the epidemiology and pathophysiology of Crohn’s disease and ulcerative colitis, highlighting prevalence, impact and unmet needs and the underlying inflammatory processes that drive IBD, considering some of the key inflammatory pathways.

Fluid Management

Fluid Management

Are you up-to-date with the latest evidence of effective procedures for fluid management?

+ 2 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/000140
Orphan designation No
Date First Approved 14-08-1997
Type Medicinal product subject to medical prescription
Marketing authorisation holder INFAI, Institut für biomedizinische Analytik & NMR-Imaging GmbH